CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial and clinical growth. The company’s flagship gene-editing therapy, CASGEVY, generated $116 million in total revenue for the year, with $54 million occurring in Q4 alone. This growth was driven by a nearly threefold increase in patient initiations compared to the previous year. To date, 147 patients have started the treatment process for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East.

Beyond its commercial success, the company is advancing a diverse ‘in vivo’ liver editing portfolio that delivers treatments directly to the body using lipid nanoparticles/LNP. Key programs include CTX310 for cardiovascular conditions and the upcoming CTX460 for alpha-1 antitrypsin deficiency, which is expected to enter clinical trials in mid-2026.

CRISPR is expanding its reach through a collaboration with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases. These therapies represent a multi-billion-dollar opportunity, with Phase 2 data for their lead Factor XI candidate expected in H2 2026. The company’s clinical pipeline continues to mature with ‘zugo-cel,’ which is a CAR-T cell therapy being tested for both autoimmune diseases like lupus and various B-cell cancers. CRISPR Therapeutics (NASDAQ:CRSP) is also making strides in regenerative medicine with CTX213, an islet cell replacement candidate for Type 1 diabetes that has shown promising preclinical efficacy.

CRISPR Therapeutics (NASDAQ:CRSP) is a gene editing company that develops gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (Cas9) platform.

While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.